Jeffrey Simmons serves as the President and CEO of Elanco Animal Health Inc., a global leader in animal health products and services. With a robust background in the pharmaceutical and animal health industries, Simmons has been instrumental in steering Elanco towards significant growth and innovation. Before joining Elanco, he held several key leadership positions, including President of Lilly Diabetes and President of Lilly USA, both part of Eli Lilly and Company. His experience at Eli Lilly, where he spent over two decades, honed his skills in strategic planning, business development, and global operations. Under Simmons' leadership, Elanco has expanded its portfolio through strategic acquisitions and intensified its focus on research and development. Notable achievements during his tenure include the successful spin-off of Elanco from Eli Lilly in 2018, positioning the company as an independent entity on the New York Stock Exchange. Simmons has also driven the company's commitment to sustainability and innovation, launching initiatives aimed at improving animal health and food security worldwide. His vision for Elanco includes leveraging technology and data analytics to enhance product offerings and customer engagement, ensuring the company remains at the forefront of the animal health industry. As President and CEO, Simmons is responsible for overseeing Elanco's global operations, setting the strategic direction, and fostering a culture of excellence and innovation. He actively engages with stakeholders, including employees, customers, and investors, to align the company's goals with broader industry trends and societal needs. His leadership style emphasizes collaboration, transparency, and a relentless focus on delivering value, which has been pivotal in establishing Elanco as a trusted name in animal health.